Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2010
Business Overview: Repligen is an integrated biopharmaceutical company focused on developing therapies for neurology and gastroenterology (e.g., Friedreich's ataxia, spinal muscular atrophy) and operating a bioprocessing business selling recombinant Protein A products. A significant portion of revenue is derived from royalties on Bristol-Myers Squibb's Orencia® sales.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Six Months Ended Sep 30, 2010 |
|---|---|---|
| Total Revenue | $7,306,978 | $14,316,850 |
| Net Income (Loss) | $623,209 | $1,611,262 |
| Operating Income (Loss) | $526,530 | $1,415,625 |
| EPS (Diluted) | $0.02 | $0.05 |
| Cash & Cash Equivalents | $15,163,290 | $15,163,290 (Balance Sheet) |
| Total Marketable Securities | $44,527,893 | $44,527,893 (Balance Sheet) |
| Working Capital | $60,551,729 | $60,551,729 (Calculated) |
| Total Liabilities | $4,365,457 | $4,365,457 (Balance Sheet) |
Note: The company reported a net income for the first time in recent periods, reversing prior losses. Operating cash flow for the six-month period was $673,727.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 35% ($1.89M) for the quarter and 37% ($3.84M) for the six-month period compared to the prior year.
- Product Revenue: Increased 61% ($1.67M) for the quarter and 67% ($3.47M) for the six months, driven by a rebound in orders from the largest bioprocessing customer.
- Royalty Revenue: Increased due to higher sales of Orencia® by Bristol-Myers Squibb. Bristol royalties represented 34% of total revenue for the quarter and 35% for the six months.
- Profitability: The company transitioned from a net loss of $979,703 (quarter) and $2,085,683 (six months) in the prior year to net income of $623,209 and $1,611,262, respectively.
- Operating Expenses:
- R&D: Decreased 10% ($360k) for the quarter and 15% ($1.05M) for the six months, primarily due to the completion of Phase 3 clinical operations for RG1068 and reduced activity in the RG2417 bipolar depression trial.
- SG&A: Decreased 4% ($76k) for the quarter but increased 6% ($195k) for the six months due to headcount expansion.
- Liquidity: Total cash and marketable securities increased to approximately $59.7 million, up from $59.1 million at the end of the prior fiscal year.
Outlook, Risks, and Unusual Items
- Guidance: Management does not provide specific forward-looking financial guidance due to the volatility of bioprocessing orders and the uncertainty of drug development timelines. They believe current cash balances are adequate for the foreseeable future absent major acquisitions.
- Revenue Concentration Risk:
- Bristol-Myers Squibb royalties accounted for 34-35% of total revenue.
- The largest bioprocessing customer accounted for 46-50% of total revenue.
- As of September 30, 2010, Bristol royalties represented 55% of accounts receivable.
- Development Risks: Future revenue from therapeutic candidates (e.g., for Friedreich's ataxia, SMA) is uncertain. The company relies on grants and royalties to fund R&D.
- Unusual Items:
- Subsequent Event: On October 29, 2010, the company received approximately $733,000 in grants under the Qualifying Therapeutic Discovery Project Program.
- Acquisition: In January 2010, the company acquired BioFlash assets for $2.6 million, including a contingent consideration liability of $560,000.
- Tax Status: The effective tax rate was 0% due to the utilization of net operating loss (NOL) carryforwards. A full valuation allowance remains against deferred tax assets.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the largest bioprocessing customer and Bristol-Myers Squibb's Orencia® sales trajectory, as they drive the majority of revenue.
- Cash Burn vs. Runway: Confirm that the $59.7M cash position is sufficient to fund ongoing R&D programs (SMA, Friedreich's ataxia) without immediate dilution, given the lack of product revenue from therapeutic candidates.
- R&D Milestones: Monitor progress on the Spinal Muscular Atrophy (SMA) program and Friedreich's ataxia trials, as these represent the primary growth potential beyond current royalties.
- Inventory Valuation: Review inventory levels ($2.0M) and potential obsolescence risks, as manufacturing is done to order but demand can fluctuate.
- Grant Dependency: Assess the sustainability of revenue from research grants (e.g., Muscular Dystrophy Association) which contributed to the "Royalty and other revenue" line.